Trials / Terminated
TerminatedNCT01897714
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Oncopeptides AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will explore escalating doses of melflufen in combination with dexamethasone in small groups of patients to find the maximum tolerated dose of melflufen. That dose will then be used to determine the efficacy and safety profile of melflufen in combination with dexamethasone in a larger group of patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Melflufen | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2017-12-01
- Completion
- 2020-03-01
- First posted
- 2013-07-12
- Last updated
- 2020-10-23
- Results posted
- 2020-08-24
Locations
7 sites across 5 countries: United States, Denmark, Italy, Netherlands, Sweden
Source: ClinicalTrials.gov record NCT01897714. Inclusion in this directory is not an endorsement.